美國居民不適用 XM 服務。
Q
Q

QIEN

財經新聞

Germany corporate earnings week ahead

DIARY-Germany corporate earnings week ahead July 26 (Reuters) - Diary of Germany (.GDAXI) corporate earnings for the week ahead GERMANY EARNINGS Start Date Start Time (GMT) RIC Company Name Event Name 30-Jul-2024 NTS 1COV.DE Covestro AG Half Year 2024 Covestro AG Earnings Release 30-Jul-2024 BMO HEIG.DE Heidelberg Materials AG Half Year 2024 Heidelberg Materials AG Earnings Release 30-Jul-2024 04:30 AIR.PA Airbus SE Half Year 2024 Airbus SE Earnings Release 31-Jul-2024 AMC QGEN.N Qiagen NV Q2 20
A
A
B
F
M
P
S
S
V
V
Q
G

Qiagen NV Sees At Least $2 Billion Of Combined Annual Sales In 2028

BRIEF-Qiagen NV Sees At Least $2 Billion Of Combined Annual Sales In 2028 June 17 (Reuters) - Qiagen NV QIA.DE : QIAGEN NV - NEW 2028 TARGETS INCLUDES PLANS TO RETURN AT LEAST $1 BILLION TO SHAREHOLDERS FROM 2024-2028 QIAGEN NV SEES ABOUT 7% COMPOUND ANNUAL SALES GROWTH AT CONSTANT EXCHANGE RATES THROUGH 2024-2028 QIAGEN NV - HAS SET A GOAL FOR AT
Q

Qiagen eyes sales growth of 7% per year until 2028

Qiagen eyes sales growth of 7% per year until 2028 FRANKFURT, June 17 (Reuters) - Diagnostics company Qiagen QIA.DE said on Monday it was targeting 7% currency-adjusted sales growth per year until 2028 on lab testing machines for infections and cancer, as it maps out its post-pandemic strategy. Holding an investor event on Monday, it also issued a goal for adjusted operating income margin of at least 31% in 2028, up from 26.9% in 2023, by winding down unprofitable products and simplifying the or
Q

Evotec and Qiagen enter software collaboration for insights into multi-omics data

BRIEF-Evotec and Qiagen enter software collaboration for insights into multi-omics data June 3 (Reuters) - EVOTEC SE EVTG.DE : EVOTEC AND QIAGEN ENTER SOFTWARE COLLABORATION FOR BETTER INSIGHT INTO MULTI-OMICS DATA Further company coverage: EVTG.DE (Gdansk Newsroom)
Q

QIAGEN And Myriad Genetics Develop Distributable Homologous Recombination Deficiency Test

BRIEF-QIAGEN And Myriad Genetics Develop Distributable Homologous Recombination Deficiency Test May 31 (Reuters) - QIAGEN NV QIA.DE : SAID ON THURSDAY: QIAGEN AND MYRIAD GENETICS DEVELOP DISTRIBUTABLE HOMOLOGOUS RECOMBINATION DEFICIENCY TEST FOR GLOBAL RESEARCH AND COMPANION DIAGNOSTICS APPLICATIONS Further company coverage: QIA.DE (Gdansk Newsroom
Q

細節

熱門資產

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明